Location · Arkansas
Clinical trials recruiting in Arkansas
255 recruiting studies have at least one site in Arkansas; 48 accept healthy volunteers. Studies that need a specific condition are included too, so check each listing.
Want the research companies that run paid Phase 1 studies for healthy volunteers? Paid clinical trial companies in Arkansas.
255 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- Recruiting
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
Endologix
- Location
- Fayetteville, AR + 24 other US sites
- Eligibility basics
- Ages 21+
- Recruiting
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
BrioHealth Solutions, Inc.
- Location
- Little Rock, AR + 46 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
52-week Open Label Safety-Tolerability Study
LB Pharmaceuticals Inc.
- Location
- Bentonville, AR + 22 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Axsome Therapeutics, Inc.
- Location
- Little Rock, AR + 48 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
AbbVie
- Location
- Little Rock, AR + 11 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 2
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Apollo Therapeutics Ltd
- Location
- Bryant, AR + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
Cytokinetics
- Location
- Little Rock, AR + 23 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 3
Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients With Lumbar Degenerative Disc Disease
CGBio Inc.
- Location
- Little Rock, AR + 7 other US sites
- Eligibility basics
- Ages 21–80
- RecruitingPhase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
Relay Therapeutics, Inc.
- Location
- Little Rock, AR + 21 other US sites
- Eligibility basics
- Ages 2+
- RecruitingPhase 2
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
Protara Therapeutics
- Location
- Little Rock, AR + 8 other US sites
- Eligibility basics
- Ages 6 mo–18
- RecruitingPhase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
AstraZeneca
- Location
- Little Rock, AR + 206 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Amgen
- Location
- Little Rock, AR + 193 other US sites
- Eligibility basics
- Ages 50–105
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Little Rock, AR + 111 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
GlaxoSmithKline
- Location
- Little Rock, AR + 13 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc.
- Location
- Little Rock, AR + 14 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
AbbVie
- Location
- Bryant, AR + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Bryant, AR + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company
- Location
- Little Rock, AR + 39 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis
Panafina, Inc.
- Location
- Little Rock, AR + 9 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 2
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
CSL Behring
- Location
- Little Rock, AR + 8 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
BlueRock Therapeutics
- Location
- Little Rock, AR + 33 other US sites
- Eligibility basics
- Ages 45–75
- RecruitingPhase 2
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
Novartis Pharmaceuticals
- Location
- Bentonville, AR + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 4
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
Bausch Health Americas, Inc.
- Location
- Bryant, AR + 13 other US sites
- Eligibility basics
- Ages 9–11
- RecruitingPhase 2
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
- Location
- Little Rock, AR + 21 other US sites
- Eligibility basics
- Ages 12–55